AKT1 and cancer: RTK reactivation leads to the initiation of the parallel PI3K/AKT signaling, which represents the primary mechanism of MEKI resistance in cancer cells and the leading mechanism driving cell proliferation and tumorigenesis in MEKI-treated cancer cells (206, 207).